Effects Of Different Doses Of Recombinant Human Growth Hormone Treatment In Children Born Small For Gestational Age

Research BackgroundSmall gestational age(SGA)is defined as birth weight and / or length of newborns at least two standard deviations(SDs)below the mean or lower the normal reference value of the 10 th percentile for gestational age[1,2].It is estimated that 6.61%of newborns are small for gestational age,premature infant in 13.1%,term births in6.05% [3,4].Eighty to ninety percent of SGA children will experience spontaneous catch-up growth and achieve a normal height genetic potential.Still,ten to twenty percent of these children will not have catch-up growth,and the cause for this is unknown[5,6].After age 4 years,spontaneous catchup becomes very unlikely[7,8].In2001,the Food and Drug Administration(FDA)approved the use of recombinant human growth hormone(rhGH)for the treatment of these children[9].Previous studies have found that recombinant human growth hormone(rhGH)treatment in SGA effective,but there is no uniform dose of treatment standards.The aim of this study was to provide the basis for clinical treatment by comparing the therapeutic effects of different doses of rhGH treatment in children born small for gestational.To evaluate the effects of different doses of recombinant human growth hormone(rhGH)treatment in children born small for gestational age without catch-up growth and to provide the basis individual clinical treatment for them.MethodsA total of 32 children who survived SGA were enrolled in the Third Clinical College of Zhengzhou University from September 2014 to September 2015.Among them,there were 13 boys and 19 girls,aged 4 to 8 years,mean age(average age)6.11± 1.74)years old.In the standard [10]:(1)birth weight and length lower than the same age,the same sex reference value of the first 10 percent;(2)greater than or equal to4 years of age is still lower than the same age,same sex,with the average height of the normal children of the two standard deviation;(3)growth hormone stimulated test peak?10?g/L,except for growth hormone deficiency;chromosomal abnormalities,genetic metabolic diseases,systemic systemic disease,never participated in rhGH treatment.There were no significant differences in gender and age between the two groups(P>0.05).The difference was statistically significant(P>0.05).ResultsThere was no significant difference in age,BMI,GV,HtSDS,insulin-link growth factor(IGF-1),insulin link growth factor binding protein-3(IGFBP-3),glucose(GLU),free T4(FT4)and thyroid stimulating hormone(TSH)between the high dose group and the low dose group before rhGH treatment was given(P>0.05).After treatment with rhGH for 12 months,the GV was(11.03 ± 2.73)cm / y in the high dose group and(8.21 ± 2.35)cm / y in the low dose group.The HtSDS was(-1.42±0.19)in the high dose group,the Ht SDS was(-1.95±0.37)in the low dose group,and the difference was statistically(P<0.05).The BMI was not statistically significant(P>0.05).The high dose group was higher than the low dose group,and the difference was statistically(P<0.05),suggesting that the efficacy of high-dose group is better than the low dose group.The difference of IGF-1 and ObjectiveIGFBP-3,GLU,FT4 and TSH was not statistically significant(P>0.05).IGF-1 and IGFBP-3 had increased after rhGH treatment.Conclusion(1)This study had found that rhGH treatment in SGA effective,different doses all can significant promote the grow velocity of children born small for gestational age;(2)The effect of high dose of rhGH treatment was significantly better than that of low dose,and high dose did not increase the incidence of obesity,abnormal glucose,abnormal thyroid function.